247 results
8-K
EX-99.1
DRRX
Durect Corp
30 Apr 24
Other Events
2:30pm
the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today … , potentially leading to life-threatening complications including liver failure, acute kidney injury and multi-organ failure. There are no FDA approved
8-K
EX-99.1
DRRX
Durect Corp
27 Mar 24
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:15pm
including liver failure, acute kidney injury and multi-organ failure. There are no FDA approved therapies for AH and a retrospective analysis of 77 studies … , the proposed mechanism of action provides further scientific rationale for developing larsucosterol for the treatment of acute organ injury and certain chronic
8-K
EX-99.1
DRRX
Durect Corp
4 Mar 24
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
11:37am
to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate
8-K
EX-99.1
8rsxun2l
13 Nov 23
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
4:15pm
8-K
EX-99.1
1kjkmn0aak91fncry
7 Nov 23
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
4:10pm
8-K
EX-99.1
pavylv455e x7sn02zld
7 Sep 23
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial
9:02am
8-K
EX-99.1
h9glhnkyfu8ol
9 Aug 23
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
4:23pm
8-K
EX-99.1
ddjzz3 nij8g9
21 Jul 23
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
5:13pm
8-K
EX-99.1
6an4qb 0h01dis8tb6
7 Jun 23
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
9:00am
8-K
EX-99.1
3x07bp9 pf85kutla
16 May 23
Regulation FD Disclosure
12:08pm
8-K
EX-99.1
n1oln6d
8 May 23
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
4:15pm
8-K
EX-99.1
rsq4h0
10 Apr 23
Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023
9:30am
8-K
EX-99.1
sxhdb4mbt
28 Nov 22
DURECT Announces 1-for-10 Reverse Stock Split
7:31pm
8-K
EX-99.1
maig45 wxn
2 Nov 22
DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
4:16pm
8-K
EX-99.1
e2fe2qd8
6 Oct 22
Other Events
9:01am
8-K
EX-99.1
7mlpxj5r5hz 60hcmb
26 Sep 22
Other Events
9:00am